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Introduction
Proteasome inhibition with bortezomib is a cornerstone in the treatment of multiple myeloma (MM). Initially approved as single agent for the treatment of relapsed disease, bortezomib is used in frontline therapy for transplant-eligible and ineligible patients. Bortezomib prolonged progression-free and overall survival as induction therapy in candidates for autologous stem cell transplantation (ASCT) (1, 2) . In patients with relapsed MM, Moreau et al. demonstrated with the randomized, prospective MMY-3012 study that subcutaneous (SC) administration of bortezomib reduced toxicity without loss of efficacy compared to the conventional intravenous (IV) bolus injections (3, 4) . Limited data are available on toxicity and efficacy of SC bortezomib as combination partner in newly diagnosed, transplant-eligible patients (5, 6 ).
The primary end-points of the randomized, prospective MM5 phase III trial of the German-Speaking Myeloma Multicenter Group (GMMG) were response to VCD (bortezomib, cyclophosphamide, dexamethasone) compared to PAd (bortezomib, doxorubicin, dexamethasone) induction therapy with respect to high-quality remissions (very good partial response or better [≥VGPR] ) and progression-free survival (PFS) (7) . Based on the data published by Moreau et al., the route of administration for bortezomib was changed from IV to SC in both trial arms after 314 of the planned 504 patients were enrolled in the MM5 trial. By a protocol amendment the recruitment of 100 additional patients was stated to get comparable group sizes for IV and SC bortezomib administration. Therefore, we were able to perform the largest explorative analysis comparing toxicity and efficacy of IV and SC bortezomib in two-different induction therapies for newly diagnosed MM.
Methods

Patients
Patients with newly diagnosed symptomatic MM according to CRAB criteria (8) 
Study design
The trial was designed to assess two primary objectives: 1. Demonstrating noninferiority of VCD to PAd induction therapy with respect to rates of VGPR or better (≥VGPR). 2. Determination of the best treatment strategy with respect to PFS.
Treatment was defined by PAd vs. VCD induction therapy; high dose melphalan followed by ASCT as well as consolidation and maintenance therapies with lenalidomide for 2 years or until complete response (Figure 1) . Recruitment of the final 604 patients was completed in 11/2013.
Induction therapy
Patients' randomization was stratified by International Staging System (ISS) (9) recommendations that were modified to include near complete remission (nCR) (10) .
Interphase FISH analysis was accomplished on CD138-purified plasma cells to identify cytogenetic abnormalities (CA). As described previously, deletion 17p, t (4;14) and gain 1q21 > 2 copies were defined as adverse CA (11) .
Statistical analysis
Comparison of IV versus SC bortezomib in PAd and VCD was performed after 604 
Results
Patient cohort
Out of 604 randomized patients, 6 patients did not receive the allocated trial medication and were excluded from the safety population. In total, 296 patients were treated with PAd and 302 patients with VCD. In both arms 51% of patients were treated with IV (PAd n=150; VCD n=154) and 46-47% with SC bortezomib (PAd n=140; VCD n=140). Since route of administration was changed during ongoing induction therapy, 14 patients were excluded from the current analysis. The consort diagram is depicted in Figure 2 . Patient baseline characteristics are summarized in Table 1 .
Trial medication
In the PAd group 92% of IV-treated and 97% of SC-treated patients completed the scheduled 3 cycles. In the VCD arm, 98% of both IV-and SC-treated patients completed 3 cycles. Proportions of patients receiving scheduled or delayed full dose trial medication and dose modifications for bortezomib are available as supplemental material (supplemental Table 1 ). Cumulative bortezomib doses (mg) were significantly higher for SC-treated patients in both arms (median doses PAd: IV=27.6 / SC=28.9; VCD: IV=27.9 / SC=28.8, p = 0.04).
Safety and toxicity
Safety profiles of SC and IV bortezomib are shown in Table 2 . AEs grade There were no significant differences in reversibility of PN between SC-and IV-treated patients, since in both groups 36% of patients showed no improvement of PN (Table 2) .
Furthermore, IV-treated patients had significantly higher rates of gastrointestinal (10% versus 4%; p = 0.006) as well as metabolism and nutrition disorders (13% versus 5%; p = 0.004). No significant differences were found for serious adverse events (SAEs) or deaths related to induction therapy ( Table 2) .
Response
There were no significant differences in overall response rates (ORR, defined by partial response [PR] or better) among IV-and SC-treated patients in PAd (IV=73%; SC=71%) and VCD group (IV=78%; SC=82%, Table 3 ).
Analysis of high quality responses revealed that IV-treated patients in the VCD arm Table 3 ).
Subgroup analysis of patients with CA, baseline creatinine values > 2mg/dl or ISS III did not reveal significant differences in ORR between IV and SC bortezomib in both arms (Table 3) .
Discussion
The present explorative analysis of the GMMG MM5 study represents to our knowledge the largest comparison of IV and SC bortezomib from a prospective trial in newly diagnosed MM. We confirm data presented by Moreau et al. for relapsed disease (3). We also observed reduced toxicity and non-inferiority in terms of ORR.
The presence of ISS III, renal impairment or CA at initial presentation had no negative impact on ORR in SC and IV-treated patients.
Early phase I trials of bortezomib in relapsed MM identified gastrointestinal (GI) as well as metabolic disorders (e.g. hypokalemia, hyponatremia) and PN as dose limiting toxicities (12, 13) . With our current study we demonstrate that the mentioned AEs can be reduced by SC application of bortezomib, which is in line with data from Differences in PN between SC-and IV-treated patients became evident in the last (3 rd ) cycle of induction therapy. An explanation for this finding is the cumulative dosedependent occurrence of PN in IV-treated patients (14) . In MMY-3021 the cumulative bortezomib dose was also linked to incidence of PN in SC-treated patients. However, for the same dose, PN was less frequent with SC compared to IV bortezomib (3).
Because PN leads to dose reductions, in our study and in MMY-3021 cumulative doses were higher in SC-treated compared to IV-treated patients (3). An explanation for reduced PN rates despite higher cumulative doses after SC application is that maximum bortezomib plasma concentrations are lower compared to IV bolus injections (15, 16) . Since recent studies identified tumor and host factors associated with susceptibility for bortezomib-induced neuropathy (BiPN) (17, 18) , the decisive factor remains uncertain. These studies underline that drug exposure alone does not determine the occurrence of BiPN.
Thrombocytopenia is the most frequent dose limiting hematological toxicity of bortezomib (13) . Contrary to the MMY-3021 study that showed reduced thrombocytopenias in SC-treated patients (3), no difference in grade In both studies and MMY-3021 response assessment was performed after four cycles, while in MM5 only three cycles induction therapy were applied. Several phase II and phase III trials of bortezomib-based induction therapies reported higher rates of ≥ VGPR after four to six cycles (22) . Reduced toxicity of SC bortezomib demonstrated with the current study enables prolonged pre-transplant treatment to achieve higher rates of ≥ VGPR that are important predictors for survival after ASCT (23).
The question concerning combination partners in bortezomib-based induction therapies remains also controversial (1, 22) . The MM5 trial was the first phase III trial to show non-inferiority of two different bortezomib-based induction therapies with respect to rates of ≥ VGPR (7). Additionally, favorable toxicity of VCD over PAd was demonstrated (7). We therefore recommend VCD as induction therapy before ASCT.
Immunomodulatory drugs like thalidomide and lenalidomide (24) There are limitations to the present analysis, since the MM5 trial was not designed to prospectively evaluate toxicity and efficacy of IV and SC bortezomib in PAd or VCD.
Furthermore, longer follow-up is needed to evaluate whether lower rates of ≥ VGPR in SC-treated patients will lead to differences in progression-free and overall survival after ASCT and lenalidomide consolidation / maintenance therapy.
In conclusion, SC compared to IV bortezomib in PAd and VCD induction therapy reduced toxicity and achieved similar ORR, regardless whether adverse prognostic factors like ISS III, renal impairment or CA were present at primary diagnosis. 
